Randomized, investigator-blinded, multicenter, comparative study of gatifloxacin versus amoxicillin/clavulanate in recurrent otitis media and acute otitis media treatment failure in children

Pediatric Infectious Disease Journal

Volumn 24, Issue 4, 2005, Pages 301-308

  Sher, Lawrence ^a   Arguedas, Adriano ^b   Husseman, Michael ^c   Pichichero, Michael ^d   Hamed, Kamal A ^e   Biswas, Debjit ^e   Pierce, Phillip ^e   Echols, Roger ^e  

^a Peninsula Research Associates   (United States)

^b HOSPITAL NACIONAL DE NIÑOS   (Costa Rica)

^c Wee Care Pediatrics   (United States)

^d UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^e BRISTOL MYERS SQUIBB   (United States)

Author keywords

Amoxicillin clavulanate; Fluoroquinolones; Gatifloxacin; Otitis media; Recurrent otitis media

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; GATIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

AGE DISTRIBUTION; ANTIBIOTIC RESISTANCE; ARTHRALGIA; ARTHROPATHY; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG TOLERANCE; FEMALE; FOLLOW UP; GAIT DISORDER; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYRINGOTOMY; OTITIS MEDIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; REVIEW; SIDE EFFECT; SINGLE BLIND PROCEDURE; TREATMENT FAILURE; TREATMENT OUTCOME;

ACUTE DISEASE; AMOXICILLIN-POTASSIUM CLAVULANATE COMBINATION; ANTI-INFECTIVE AGENTS; CHILD; CHILD, PRESCHOOL; FEMALE; FLUOROQUINOLONES; HAEMOPHILUS INFECTIONS; HAEMOPHILUS INFLUENZAE; HUMANS; INFANT; MALE; OTITIS MEDIA; PNEUMOCOCCAL INFECTIONS; RECURRENCE; SINGLE-BLIND METHOD; STREPTOCOCCUS PNEUMONIAE; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 17144375625     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.inf.0000157084.35865.ba     Document Type: Review

References (28)

1. Pichichero ME, Casey JR. Otitis media. Expert Opin Pharmacother. 2002;3:1073-1090.
2. Hendley JO. Otitis media. N Engl J Med. 2002;347:1169-1174.
3. Pichichero ME. Recurrent and persistent otitis media. Pediatr Infect Dis J. 2000;19:911-916.
4. Hoberman A, Marchant CD, Kaplan SL, Feldman S. Treatment of otitis media consensus recommendations. Clin Pediatr. 2002;41:373-390.
5. Loundon N, Roger G, Thien HV, Bégué P, Garabédian EN. Evolution of the bacteriologic features of persistent acute otitis media compared with acute otitis media. A 15-year study. Arch Otolaryngol Head Neck Surg. 1999;125:1134-1140.
6. Block SL, Hedrick JA, Tyler RD, et al. Microbiology of acute otitis media recently treated with aminopenicillins. Pediatr Infect Dis J. 2001;20:1017-1021.
7. Babin E, Lemarchand V, Moreau S, Goullet de Rugy M, Valdazo A, Bequignon A. Failure of antibiotic therapy in acute otitis media. J Laryngol Otol. 2003;117:173-176.
8. Gehanno P, N'Guyen LN, Derriennic M, Pichon F, Goehrs JM, Berche P. Pathogens isolated during treatment failures in otitis. Pediatr Infect Dis J. 1998;17:885-890.
9. Leibovitz E, Raiz S, Piglansky L, et al. Resistance pattern of middle ear fluid isolates in acute otitis media recently treated with antibiotics. Pediatr Infect Dis J. 1998;17:463-469.
10. Subcommittee on Management of Acute Otits Media. American Academy of Pediatrics and American Academy of Family Physicians. Clinical practice guideline: diagnosis and management of acute otitis media. Pediatrics. 2004;113:1451-1465.
11. Piglansky L, Leibovitz E, Raiz S, et al. Bacteriologic and clinical efficacy of high dose amoxicillin for therapy of acute otitis media in children. Pediatr Infect Dis J. 2003;22:405-413.
12. Burkhardt JE, Walterspiel JN, Schaad UB. Quinolone arthropathy in animals versus children. Clin Infect Dis. 1997;25:1196-1204.
13. Alghasham AA, Nahata MC. Clinical use of fluoroquinolones in children. Ann Pharmacother. 2000;34:347-359.
14. Food and Drug Administration Anti-Infective Drugs Advisory Committee. Sixty-second meeting; November 1997; Bethesda, MD.
15. Perry CM, Ormrod D, Hurst M, Onrust SV. Gatifloxacin: a review of its use in the management of bacterial infections. Drugs. 2002;62:169-207.
16. Jones RN, Pfaller MA. In vitro activity of newer fluoroquinolones for respiratory tract infections and emerging patterns of antimicrobial resistance: data from the SENTRY Antimicrobial Surveillance Program. Clin Infect Dis. 2000;31 (suppl 2):S16-S23.
17. Fish DN, North DS. Gatifloxacin, an advanced 8-methoxyfluoroquinolone. Pharmacotherapy. 2001;21:35-59.
18. Arguedas A, Sher L, Lopez E, et al. Open label, multicenter study of gatifloxacin treatment of recurrent otitis media and acute otitis media treatment failure. Pediatr Infect Dis J. 2003;22:949-956.
19. Leibovitz E, Piglansky L, Raiz S, et al. Bacteriologic and clinical efficacy of oral gatifloxacin for the treatment of recurrent/nonresponsive acute otitis media: an open label, noncomparative, double tympanocentesis study. Pediatr Infect Dis J. 2003;22:943-949.
20. Dagan R, Leibovitz E, Greenberg D, et al. Early eradication of pathogens from middle ear fluid during antibiotic treatment of acute otitis media is associated with improved clinical outcome. Pediatr Infect Dis J. 1998;17:776-782.
21. Fleiss JL. Statistical Methods for Rates and Proportions. 2nd ed. New York:John Wiley & Sons, 1981.
22. Saez-Llorens X, Rodriquez A, Arguedas A, et al. Gatifloxacin (GAT) vs. amoxicillin/clavulanate (AC) for the treatment of recurrent otitis media (ROM) and acute otitis media treatment failures (OMTF). Presented at the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, September 14-17, 2003, Chicago, IL. Poster G-1849.
23. Schaad UB, Stoupis C, Wedgwood J, Tschaeppeler H, Vock P. Clinical, radiologic and magnetic resonance monitoring for skeletal toxicity in pediatric patients with cystic fibrosis receiving a three-month course of ciprofloxacin. Pediatr Infect Dis J. 1991;10:723-729.
24. Schaad UB, Sander E, Wedgwood J, Schaffner T. Morphologic studies for skeletal toxicity after prolonged ciprofloxacin therapy in two juvenile cystic fibrosis patients. Pediatr Infect Dis J. 1992;11:1047-1049.
25. Yee CL, Duffy C, Gerbino PG, Stryker S, Noel GJ. Tendon or joint disorders in children after treatment with fluoroquinolones or azithromycin. Pediatr Infect Dis J. 2002;21:525-529.
26. Mandell LA, Peterson LR, Wise R, et al. The battle against emerging antibiotic resistance: should fluoroquinolones be used to treat children? Clin Infect Dis. 2002;35:721-727.
27. Fukuda H, Hiramatsu K. Primary targets of fluoroquinolones in Streptococcus pneumoniae. Antimicrob Agents Chemother. 1999;43:410-412.
28. Schmitz F-J, Boos M, Mayer S, et al. Propensity of fluoroquinolones with different moieties at position 8 to cause resistance development in clinical isolates of Streptococcus pneumoniae [letter]. Antimicrob Agents Chemother. 2001;45:2666-2667.